These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Experience with the treatment of multiple sclerosis with proper-myl]. Briantseva RG Zh Nevropatol Psikhiatr Im S S Korsakova; 1968; 67(8):1180-2. PubMed ID: 5680529 [No Abstract] [Full Text] [Related]
9. Intrathecal methylprednisolone acetate in multiple sclerosis treatment. Clinical evaluation. Mazzarello P; Poloni M; Piccolo G; Cosi V; Pinelli P Acta Neurol Belg; 1983; 83(4):190-6. PubMed ID: 6689244 [TBL] [Abstract][Full Text] [Related]
10. [Lumbar intrathecal injection of methylprednisolone acetate in the treatment of multiple sclerosis]. Delzanno GB; Jann G Clin Ter; 1969 Jan; 48(2):151-5. PubMed ID: 5409031 [No Abstract] [Full Text] [Related]
11. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872 [TBL] [Abstract][Full Text] [Related]
12. The treatment of multiple sclerosis with intrathecally administered methylprednisolone acetate. Ringer WA J Indiana State Med Assoc; 1968 Sep; 61(9):1213-5. PubMed ID: 5695699 [No Abstract] [Full Text] [Related]
13. [Interferon therapy of multiple sclerosis]. Jensen D Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481 [TBL] [Abstract][Full Text] [Related]
14. [Our observations regarding the treatment of multiple sclerosis with TFX "Polfa"]. Fryze W; Obiedziński R Neurol Neurochir Pol; 1988; 22(5):475. PubMed ID: 3249619 [No Abstract] [Full Text] [Related]
15. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854 [TBL] [Abstract][Full Text] [Related]
16. [Evaluation of therapeutic effect of intramuscular proper-myl injections in multiple sclerosis]. Mularek O Neurol Neurochir Pol; 1969; 3(4):469-73. PubMed ID: 4897304 [No Abstract] [Full Text] [Related]
17. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154 [TBL] [Abstract][Full Text] [Related]
18. [Our contemporary experiences with the intrathecal treatment of multiple sclerosis using depot corticoids. I. Clinical results]. Hanák L; Zouhar A Cesk Neurol Neurochir; 1974 Sep; 37(5):287-92. PubMed ID: 4479028 [No Abstract] [Full Text] [Related]
19. [Biochemical and immunologic research in multiple sclerosis]. Szabó S Acta Neurol Psychiatr Belg; 1968 Sep; 68(9):682-704. PubMed ID: 4180713 [No Abstract] [Full Text] [Related]
20. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a. Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]